Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network-Reference-Cited by-同舟云学术

Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network

Published:2022-11-15 Issue:Supplement 1 Volume:140 Page:1-3
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Dreyling Martin¹,Doorduijn Jeanette K.²,Gine Eva³,Jerkeman Mats⁴,Walewski Jan⁵,Hutchings Martin⁶,Mey Ulrich⁷⁸,Riise Jon⁹,Trneny Marek¹⁰,Vergote Vibeke K.J.¹¹,Celli Melania¹²,Shpilberg Ofer¹³,Gomes da Silva Maria¹⁴,Leppa Sirpa¹⁵,Jiang Linmiao¹⁶,Pott Christiane¹⁷,Klapper Wolfram¹⁸,Gözel Döndü¹,Schmidt Christian¹,Unterhalt Michael¹,Ladetto Marco¹⁹,Hoster Eva²⁰¹

Affiliation:

1. 1Department of Internal Medicine III, LMU University Hospital Munich, Munich, Germany

2. 2Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands

3. 3Department of Hematology, Hospital Clinic of Barcelona, IDIBAPS, CIBERONC, GELTAMO, Barcelona, Spain

4. 4Division of Oncology, Skane University Hospital and Lund University, Lund, Sweden

5. 5Department of Lymphoid Malignancies, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland

6. 6Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

7. 7Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland

8. 8Oncology and Hematology, Kantonsspital Graubünden, Chur, Switzerland

9. 9Department of Oncology, Oslo University Hospital, Oslo, Norway

10. 10First Department of Internal Medicine - Hematology, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic

11. 11Department of Hematology, University Hospitals Leuven, Leuven, Belgium

12. 12U.O. di Ematologia, Ospedale degli Infermi di Rimini, Rimini, Italy

13. 13Institute of Hematology, Assuta Medical Centers, Tel-Aviv, Israel

14. 14Department of Hematology, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal

15. 15Department of Oncology, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland

16. 16Institute for Medical Information Processing, Biometry and Epidemiology (IBE), LMU University Munich, Munich, Germany

17. 17Clinic for Internal Medicine II - Haematology, Oncology, University Clinic Schleswig-Holstein, Kiel, Germany

18. 18Department of Pathology, Hematopathology Section and Lymph Node Registry, Universitätsklinikum Schleswig-Holstein, Kiel, Germany

19. 19Department of Translational Medicine, University of Eastern Piedmont and Az Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy

20. 20Institute for Medical Information Processing, Biometry and Epidemiology, LMU Munich, Munich, Germany

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas;Blood Advances;2024-09-10

2. Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL;Blood;2024-09-05

3. Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis;Blood Advances;2024-08-29

4. Stem cell collection and hematological recovery in the Fondazione Italiana Linfomi (FIL) MCL0208 clinical trial;Scientific Reports;2024-07-23

5. Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma;Blood;2024-07-18